MedTrace Logo

Relenvatinib in the Tatment of Recurrence of Hepatocellular Carcinoma After Liver Transplantation

NCT04237740 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-03-24

No results posted yet for this study

Summary

The aim of this study is to evaluate the efficacy and safety of lenvatinib in the treatment of recurrence of hepatocellular carcinoma after liver transplantation.

Conditions

Interventions

DRUG

relenvatinib

The enrolled patients are treated with lenvatinib (dose: body weight \< 60 kg: 8 mg/day, body weight ≥ 60 kg 12 mg/day).

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • qiang xia, doctor · RenJi Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2022-01-01
Completion
2022-11-01
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04237740 on ClinicalTrials.gov